

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrop⦠read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
$40.01
Price-4.28%
-$1.79
$4.081b
Mid
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-33.3%
3y CAGR-5.9%
5y CAGR-$377.939m
-53.4%
1y CAGR-41.8%
3y CAGR-31.8%
5y CAGR-$3.29
-33.2%
1y CAGR-15.8%
3y CAGR-2.2%
5y CAGR$245.488m
$404.272m
Assets$158.784m
Liabilities$108.915m
Debt26.9%
-0.3x
Debt to EBITDA-$300.637m
-49.5%
1y CAGR-32.2%
3y CAGR-24.5%
5y CAGR